Name: Preventive Nutrient Company, Inc.
Address: 18802 Maplewood Ln, Northridge, CA, 91326-3932, USA
Telephone: (818) 366-4085

Preventive Nutrient Company (PNC) Inc is a Research and Development Company which developed new, effective anti-diabetes, anti-obesity and anti-Alzheimer's disease agents. In order to expedite distribution of this important product to consumers, we are making this product available as a nutraceutical. Currently, we are performing phase 2 clinical trials on Cyclo-Z as an anti-diabetes agent for the FDA at the VA Greater Los Angeles Healthcare System. We are also in the clinical trial grant application process for the prevention and treatment of obesity and Alzheimer's diseases. The Preventive Nutrient Company will be eventually non-profit organization to promote public health research.

Body Weight Control: Cyclo-Z treatment also significantly decreased body weight (BW) or BW gain in obese and overweight animals while decreasing plasma leptin levels. Although obese subjects generally develop hyperinsulinemia (pre-diabetic), only 22% of diabetic subjects are not directly associated with Body Mass Index. Thus, obese diabetic subjects are also expected to benefit from the Cyclo-Z treatment as evidenced in the animal study. IDE deficiency causes hyperinsulinemia and hyperinsulinemia is one of the major causes of obesity, since insulin increases fat accumulation in adipocytes. Hyperinsulinemia in obesity is caused mainly by decreased insulin clearance in the plasma. Impaired internalized insulin digestion induces accumulation of inactive insulin fragments in the cells, which is associated with significant impairment of insulin receptor signal transduction mechanisms, resulting in insulin resistant, hyperinsulinemia, and obesity. Monocyte insulin levels from obese patients were more than four fold higher compared to cells from normal subjects. Similarly, plasma insulin levels in obese subjects are about 69% higher than in normal subjects. The impaired insulin clearance in obese humans and the contrasting increase in insulin clearance with weight loss has been demonstrated. The decreased insulin clearance in obese subjects is mainly due to the elevated free fatty acids which inhibit insulin degrading enzyme (IDE) synthesis. Therefore, it appears that one of the plausible methods to treat obesity may be to reduce plasma and cellular insulin levels by stimulating IDE synthesis.

Preventive Nutrient Company, Inc.

Business Info

Contact Business

Company Summary

Similar Businesses Nearby

Competitive Landscape

Payments Accepted

Hours

Photos

Business Credit Report

Facebook

Twitter

Yelp

Customer Resources

Our Company

Our Network

Site Links